Uncategorized

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA Read More »

Nomination Committee for Biovica International AB for the 2024 Annual General Meeting

Biovica International The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2023, and the Chairman of the Board.

Nomination Committee for Biovica International AB for the 2024 Annual General Meeting Read More »

Scroll to Top